Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian M Jespersen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|October 5, 2002
[The small blue pills]Christian M Jespersen
Cardiology|November 3, 2007
Myocardial stress in patients with acute cerebrovascular eventsChristian M Jespersen, Jørgen Fischer Hansen
The Journal of Thoracic and Cardiovascular Surgery|July 4, 2013
Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trialKeyvan Karkouti, Christian von Heymann, Christian M Jespersen, et al.
Thrombosis and Haemostasis|October 7, 2009
Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary reportJerrold H Levy, Ravi Gill, Nancy A Nussmeier, et al.
The Annals of Thoracic Surgery|March 25, 2014
Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operationsHoward K Song, Christian von Heymann, Christian M Jespersen, et al.
Cardiology|March 31, 2011
Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Per Winkel, Jørgen Hilden, Jørgen Fischer Hansen, et al.
Journal of Clinical Epidemiology|January 20, 2012
Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart diseaseErik Kjoller, Jorgen Hilden, Per Winkel, et al.
American Heart Journal|July 29, 2014
Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trialErik Kjøller, Jørgen Hilden, Per Winkel, et al.
European Heart Journal|March 10, 2009
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery diseaseJens Kastrup, Julia S Johansen, Per Winkel, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 27, 2010
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trialMarina J Harutyunyan, Anders B Mathiasen, Per Winkel, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|October 5, 2002
[The small blue pills]Christian M Jespersen
Cardiology|November 3, 2007
Myocardial stress in patients with acute cerebrovascular eventsChristian M Jespersen, Jørgen Fischer Hansen
The Journal of Thoracic and Cardiovascular Surgery|July 4, 2013
Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trialKeyvan Karkouti, Christian von Heymann, Christian M Jespersen, et al.
Thrombosis and Haemostasis|October 7, 2009
Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary reportJerrold H Levy, Ravi Gill, Nancy A Nussmeier, et al.
The Annals of Thoracic Surgery|March 25, 2014
Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operationsHoward K Song, Christian von Heymann, Christian M Jespersen, et al.
Cardiology|March 31, 2011
Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Per Winkel, Jørgen Hilden, Jørgen Fischer Hansen, et al.
Journal of Clinical Epidemiology|January 20, 2012
Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart diseaseErik Kjoller, Jorgen Hilden, Per Winkel, et al.
American Heart Journal|July 29, 2014
Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trialErik Kjøller, Jørgen Hilden, Per Winkel, et al.
European Heart Journal|March 10, 2009
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery diseaseJens Kastrup, Julia S Johansen, Per Winkel, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 27, 2010
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trialMarina J Harutyunyan, Anders B Mathiasen, Per Winkel, et al.
Pageof 2